Stock Events

Stock Events

Whitehawk Therapeutics 

$2.05
34
-$0.05-2.38% Tuesday 20:00

Statistics

Day High
2.19
Day Low
2.02
52W High
3.81
52W Low
1.21
Volume
62,607
Avg. Volume
379,946
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.76
0.1
0.97
1.83
Expected EPS
-0.076
Actual EPS
N/A

Financials

-245.13%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
25.98MRevenue
-63.69MNet Income

Analyst Ratings

$7.00Average Price Target
The highest estimate is 7.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AADI. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Array Technologies
ARRY
Mkt Cap1.32B
Array BioPharma, acquired by Pfizer, focuses on the discovery, development, and commercialization of targeted small molecule drugs to treat cancer, directly competing with Aadi Bioscience.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has a broad portfolio of treatments, including for cancer, and its focus on innovative therapies makes it a competitor in the oncology space where Aadi Bioscience operates.
Exelixis
EXEL
Mkt Cap10.41B
Exelixis is focused on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers, competing with Aadi Bioscience's niche.
Incyte
INCY
Mkt Cap18.35B
Incyte Corporation has a strong focus on oncology, including targeted cancer therapies, making it a direct competitor to Aadi Bioscience.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a significant investment in developing treatments for various cancers, including targeted therapies that compete with Aadi Bioscience.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a diverse oncology portfolio, including targeted therapies and precision medicine, making it a competitor in the same field as Aadi Bioscience.

About

Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Show more...
CEO
Dr. David J. Lennon Ph.D.
Employees
53
Country
US
ISIN
US00032Q1040

Listings

XNAS
US
WHWK
F
DE
3350.F
BOATS
BOATS
WHWK.BOATS

0 Comments

Share your thoughts

FAQ

What is Whitehawk Therapeutics stock price today?▼
The current price of AADI is $2.05 USD — it has decreased by -2.38% in the past 24 hours. Watch Whitehawk Therapeutics stock price performance more closely on the chart.
What is Whitehawk Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Whitehawk Therapeutics stocks are traded under the ticker AADI.
What is Whitehawk Therapeutics revenue for the last year?▼
Whitehawk Therapeutics revenue for the last year amounts to 25.98M USD.
What is Whitehawk Therapeutics net income for the last year?▼
AADI net income for the last year is -63.69M USD.
How many employees does Whitehawk Therapeutics have?▼
As of April 05, 2026, the company has 53 employees.
In which sector is Whitehawk Therapeutics located?▼
Whitehawk Therapeutics operates in the Health Care sector.
When did Whitehawk Therapeutics complete a stock split?▼
The last stock split for Whitehawk Therapeutics was on August 27, 2022 with a ratio of 1:15.
Where is Whitehawk Therapeutics headquartered?▼
Whitehawk Therapeutics is headquartered in Pacific Palisades, US.